Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3974138 | Seminars in Fetal and Neonatal Medicine | 2014 | 6 Pages |
Abstract
SummaryPrenatal screening and diagnosis of Down syndrome and other major aneuploidies may be transformed following the identification of cell-free fetal DNA in maternal plasma at the end of the last millennium. Next generation sequencing has enabled the development of tests that accurately predict the presence of fetal trisomies by analysis of cell-free DNA in maternal blood from as early as 10 weeks of gestation. These tests are now widely available in the commercial sector but are yet to be implemented in publicly led health services. In this article we discuss the technical, social, and ethical challenges that these new tests bring.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Philip Twiss, Melissa Hill, Rebecca Daley, Lyn S. Chitty,